@EricTopol: Big progress vs cancer, folks. The kind of event curves from randomized trials that we've not seen before for a couple …
Summary
Big progress against two of the most deadly cancers reported from randomized trials, as highlighted by Eric Topol during the ASCO conference.
View Cached Full Text
Cached at: 06/02/26, 09:38 PM
Big progress vs cancer, folks. The kind of event curves from randomized trials that we’ve not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO https://t.co/8a642gUMF4
Similar Articles
@EricTopol: The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the mo…
Eric Topol highlights the remarkable progress in cancer immunotherapy, with vaccines achieving cures or remissions in refractory cancers like pancreatic, melanoma, glioblastoma, renal, and triple-negative breast cancer, and directs readers to his Ground Truths newsletter for more.
@DrSamuelBHume: One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results I feel inspired and…
A standing ovation greeted the full results of Daraxonrasib, a targeted therapy for pancreatic cancer, marking a major breakthrough. The researcher expresses inspiration that nothing is undruggable anymore.
The fittest founder in the room got cancer. Here’s how he used AI to fight back.
Conno Christou, a data-driven founder, was diagnosed with a rare aggressive lymphoma after a chance discovery. He used his quantitative approach—including AI-powered health tracking—to gather multiple medical opinions and choose the most effective treatment, treating his chemotherapy like a startup marathon.
Daily pill can double survival time for deadliest cancer, trial shows
A clinical trial found that the daily pill daraxonrasib doubles survival time for patients with pancreatic cancer, offering a significant breakthrough in treatment with fewer side effects compared to chemotherapy.
ChatGPT and Cancer: How a Tech Founder Rewrote His Treatment Plan
GitLab co-founder Sid Sijbrandij open-sourced 25 TB of multi-omic tumor data and used ChatGPT-driven agents to design custom therapies, including a FAP-targeted radioligand and an mRNA vaccine, for his relapsed osteosarcoma.